Several brokerages have updated their recommendations and price targets on shares of Teva Pharmaceutical Industries Limited (NYSE: TEVA) in the last few weeks:

  • 11/17/2017 – Teva Pharmaceutical Industries Limited had its “neutral” rating reaffirmed by analysts at Mizuho. They now have a $12.00 price target on the stock, down previously from $15.00.
  • 11/14/2017 – Teva Pharmaceutical Industries Limited was given a new $10.00 price target on by analysts at Cantor Fitzgerald. They now have a “hold” rating on the stock.
  • 11/13/2017 – Teva Pharmaceutical Industries Limited was downgraded by analysts at J P Morgan Chase & Co from a “neutral” rating to an “underweight” rating. They now have a $11.00 price target on the stock, down previously from $11.48.
  • 11/12/2017 – Teva Pharmaceutical Industries Limited had its “hold” rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
  • 11/7/2017 – Teva Pharmaceutical Industries Limited was downgraded by analysts at from a “hold” rating to a “reduce” rating.
  • 11/6/2017 – Teva Pharmaceutical Industries Limited had its price target lowered by analysts at Susquehanna Bancshares Inc from $20.00 to $14.00. They now have a “positive” rating on the stock.
  • 11/6/2017 – Teva Pharmaceutical Industries Limited had its “underperform” rating reaffirmed by analysts at Credit Suisse Group. They now have a $8.00 price target on the stock, down previously from $14.00.
  • 11/5/2017 – Teva Pharmaceutical Industries Limited had its price target raised by analysts at Royal Bank Of Canada from $8.00 to $13.00. They now have an “underperform” rating on the stock.
  • 11/3/2017 – Teva Pharmaceutical Industries Limited had its “hold” rating reaffirmed by analysts at Piper Jaffray Companies. They now have a $12.00 price target on the stock.
  • 11/3/2017 – Teva Pharmaceutical Industries Limited had its price target lowered by analysts at Morgan Stanley from $14.00 to $7.00. They now have an “underweight” rating on the stock.
  • 11/3/2017 – Teva Pharmaceutical Industries Limited was downgraded by analysts at Deutsche Bank AG from a “buy” rating to a “hold” rating. They now have a $14.00 price target on the stock.
  • 11/2/2017 – Teva Pharmaceutical Industries Limited was downgraded by analysts at Wells Fargo & Company to a “market perform” rating. They now have a $11.36 price target on the stock, down previously from $17.00.
  • 10/30/2017 – Teva Pharmaceutical Industries Limited had its “hold” rating reaffirmed by analysts at Mizuho. They now have a $15.00 price target on the stock.
  • 10/30/2017 – Teva Pharmaceutical Industries Limited had its “underperform” rating reaffirmed by analysts at Royal Bank Of Canada. They now have a $13.00 price target on the stock, down previously from $15.00.
  • 10/26/2017 – Teva Pharmaceutical Industries Limited was given a new $17.00 price target on by analysts at Cantor Fitzgerald. They now have a “hold” rating on the stock. They wrote, “Today Mylan (MYL; Neutral) announced the UK High Court of Justice found all claims of Teva’s patent EP ‘355 relating to Copaxone 40mg/mL invalid based on obviousness.””
  • 10/25/2017 – Teva Pharmaceutical Industries Limited was given a new $38.00 price target on by analysts at Evercore ISI. They now have a “buy” rating on the stock.
  • 10/20/2017 – Teva Pharmaceutical Industries Limited was given a new $15.00 price target on by analysts at Royal Bank Of Canada. They now have a “sell” rating on the stock.
  • 10/20/2017 – Teva Pharmaceutical Industries Limited was given a new $19.00 price target on by analysts at Barclays PLC. They now have a “hold” rating on the stock.
  • 10/19/2017 – Teva Pharmaceutical Industries Limited was given a new $17.00 price target on by analysts at Cantor Fitzgerald. They now have a “hold” rating on the stock.
  • 10/13/2017 – Teva Pharmaceutical Industries Limited was downgraded by analysts at BidaskClub from a “sell” rating to a “strong sell” rating.
  • 10/6/2017 – Teva Pharmaceutical Industries Limited was given a new $23.00 price target on by analysts at Piper Jaffray Companies. They now have a “hold” rating on the stock.
  • 10/5/2017 – Teva Pharmaceutical Industries Limited was given a new $15.00 price target on by analysts at Morgan Stanley. They now have an “underweight” rating on the stock.
  • 10/5/2017 – Teva Pharmaceutical Industries Limited had its “market perform” rating reaffirmed by analysts at Wells Fargo & Company.
  • 10/4/2017 – Teva Pharmaceutical Industries Limited was given a new $20.00 price target on by analysts at Wells Fargo & Company. They now have a “hold” rating on the stock.
  • 10/4/2017 – Teva Pharmaceutical Industries Limited had its “market perform” rating reaffirmed by analysts at Cowen and Company. They now have a $18.00 price target on the stock, down previously from $30.00.
  • 10/4/2017 – Teva Pharmaceutical Industries Limited had its “hold” rating reaffirmed by analysts at Maxim Group. They wrote, “Shares of TEVA are under pressure in the wake of the FDA’s approval of Mylan’s ANDA for generic copaxone 3x/week & 20 mg/ml QD injection. Teva has a press release estimating the impact of the two launches to its 4Q earnings of at least $0.25. Our estimates are under review but our Hold remaining remains in-effect. We had anticipated generic copaxone (3x) but not until 2018.””
  • 10/4/2017 – Teva Pharmaceutical Industries Limited was upgraded by analysts at Zacks Investment Research from a “strong sell” rating to a “hold” rating. According to Zacks, “Pricing erosion in the U.S. generics business and the continued deterioration in Venezuela is hurting sales at Teva which led to a guidance and dividend cut in August. Teva is facing several other challenges in the form of generic competition for Copaxone, new competition for branded products and a high cost base and debt load. Also, Teva’s shares underperformed the generic industry this year so far. Nonetheless, Teva is progressing with its branded/generics drugs pipeline and is looking to strengthen its biosimilar pipeline. The Actavis Generics acquisition is contributing to growth of the Generics unit. Meanwhile, Teva is focusing on cost cutting and divestments to boost growth. However, a clear path to growth is not visible. Estimates have declined ahead of the company’s Q3 earnings release. The company also has a negative record of earnings surprises in recent quarters.”
  • 10/4/2017 – Teva Pharmaceutical Industries Limited had its “hold” rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
  • 10/4/2017 – Teva Pharmaceutical Industries Limited had its “hold” rating reaffirmed by analysts at Mizuho. They now have a $16.00 price target on the stock.
  • 10/4/2017 – Teva Pharmaceutical Industries Limited was given a new $21.00 price target on by analysts at Barclays PLC. They now have an “equal weight” rating on the stock.
  • 10/4/2017 – Teva Pharmaceutical Industries Limited had its “buy” rating reaffirmed by analysts at BTIG Research. They now have a $24.00 price target on the stock.
  • 10/2/2017 – Teva Pharmaceutical Industries Limited was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating.
  • 10/2/2017 – Teva Pharmaceutical Industries Limited was given a new $17.00 price target on by analysts at Cantor Fitzgerald. They now have a “hold” rating on the stock.
  • 9/28/2017 – Teva Pharmaceutical Industries Limited was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) traded up $0.15 on Thursday, reaching $13.48. The company had a trading volume of 11,806,900 shares, compared to its average volume of 15,437,631. Teva Pharmaceutical Industries Limited has a 12-month low of $10.85 and a 12-month high of $38.49. The firm has a market capitalization of $13,543.28, a PE ratio of 3.08 and a beta of 0.52. The company has a quick ratio of 0.66, a current ratio of 0.96 and a debt-to-equity ratio of 1.20.

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 12th. Investors of record on Tuesday, November 28th will be issued a $0.085 dividend. This represents a $0.34 dividend on an annualized basis and a yield of 2.52%. The ex-dividend date is Monday, November 27th. Teva Pharmaceutical Industries Limited’s dividend payout ratio is presently -15.80%.

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.